Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Year: 2013
Type: article
Source: Science Signaling
Institution: Merrimack Pharmaceuticals (United States)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2105325373
